Fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) for non-infarct-related arteries (IRAs) in patients with acute myocardial infarction (AMI) and multivessel disease was found to be more cost-effective and improved quality of life compared to angiography-guided PCI. A prespecified analysis of the FRAME-AMI trial showed that FFR-guided PCI increased quality-adjusted life years by 0.06 and reduced total cumulative costs per patient by $1208. The incremental cost-effectiveness ratio and incremental net monetary benefit favored FFR-guided PCI. The authors recommended considering FFR-guided PCI for non-IRA stenoses in these patients, noting its potential to achieve complete revascularization and combat rising costs in AMI. Funding was received from various sources, including Medtronic and Biotronik.
Source link
Fractional Flow Reserve-Guided PCI Cost-Effective
